California Assemblyman Paul Koretz (D-West Hollywood) introduced a bill to raise the legal smoking age in the state from 18 to 21. The objective of this research is to estimate the public health and economic impacts of raising the California legal smoking age to 21. METHODS: To estimate the health and economic impacts, we created a dynamic computer simulation model. The model simulates the California population as they age and change their smoking behavior over time. Secondary data for model parameters were obtained from publicly available sources. Population health impacts were estimated in terms of change in smoking prevalence and the change in cumulative quality-adjusted life-years (QALYs) to the California population over a 50-year period. Economic impacts were measured in monetary terms for medical cost savings, cost of law enforcement and cost of checking identification. RESULTS: Smoking prevalence among teens (age 14-17) will drop to 2.4% from current levels of 13.3%, an 82% reduction. There will be savings of 24 billion and 1.47 million QALYs will be gained over a period of 50 years compared to status quo. CONCLUSIONS: This research should prove useful to California's policy makers as they contemplate legislation to raise the state's legal smoking age. Pharmacoeconomic assessment of costs and consequences of non-ST segment evaluation ACS (NSTE ACS) by traditional anticoagulants and LMWH enoxaparin usage. METHODS: Registry 1 was produced in July 2001 by inclusion of 50 adult hospital patients in ACS from 59 clinics of Russian cities. A total of 1394 patients were with NSTE ACS, 64% of them received unfractionated heparin (UFH) and 7.4%-LMWH. Registry 2 was done in 2003 according the same criteria. A total of 1185 patients from 32 clinics were enrolled. 659 of them were with NSTE ACS, 19% were treated by UFH, 60%-by enoxaparin. Pharmacoeconomic analysis "cost-effectiveness" was succeed as: k = C2 -C1 / E2 -E1. Ñ2 and Ñ1-average value of Cost per hospital patient in Registry 2 and 1 accordingly (including costs of treatment and resource utilization). Å2 and Å1-probability of successful outcomes of the disease in Registry 2 and 1 as well, k-cost per 1% of grow of effectiveness of the treatment. RESULTS: There weren't statistical discrepancy between clinical characteristics and duration of hospitalization of patients into the Registry 1 and 2. A share of more effective treated patients has been increased in Registry 2 versus Registry 1. Probability of mortality decreased by 2.3%, reinfarct-by 6.8%, refractory angina-by 6.3% (g < 0.001). Probability of successful outcomes (E2 -E1) increased by 14.9%. Ñ2 = USD 160.68; C1 = USD 100.64; E2 = 75.9%; E1 = 61%, K = USD 4.03/ %. CONCLUSION: Probably the rise of number of successful outcomes of NSTE ACS in Registry 2 was affected by more active of LMWH enoxaparin usage. Every percentage of reduction of serious adverse effects costs extra USD 4.03 but it leads to increase in the quality of health care and decrease in expenditures on ill effects after discharge from the hospital. (40 GPs, 19 cardiologists) established a register of all patients who had received at least 60 consecutive days of VKA treatment for chronic NVAF in the preceding year. Study data were obtained from the medical record and by patient interview. VKA treatment related costs included INR tests, blood sample draws, physician consultations, nurse cost and VKA related investigations and hospitalisations. Drug costs were not considered. RESULTS: Of 535 eligible patients, 278 (52%) were interviewed. A total of 3349 INR tests were collected over a cumulative follow-up time of 259 years. The mean cost for INR tests was 69.82€/patient/year; 40.4% of blood samples were taken at the patient's home by a nurse, with a mean driving distance of 4.8 km, representing an additional cost of 6.37€ for each INR taken at home (average 33.25€/patient/year). VKA treatment generated 697 GP and 187 cardiologist face-to-face consultations, at a cost of 70.43€/patient/year. Of 79 hospitalisations reported during the study period, 14 were judged attributable to VKAs by an event adjudication committee. These hospitalisations added a further 153.99€/patient/year. CONCLUSIONS: The annual cost of ambulatory VKA follow-up was 175€ per patient. VKA related hospitalisations in this patient sample added 153.99€, but the exclusion of patients unable to be interviewed may have resulted in underestimation of costs associated with severe adverse events (stroke, death). To perform a retrospective economic evaluation of an 8-week clinical trial, comparing the efficacy of fixed daily doses of olmesartan (20 mg) versus losartan (50 mg), valsartan (80 mg) and irbesartan (150 mg) in patients with mild to moderate essential hypertension in Spain. METHODS: A costeffectiveness analysis (CEA) was carried out using 2004 drug acquisition costs for ARA-II evaluated, and proportion of patients with controlled blood pressure (BP; diastolic BP < 90 mmHg or a reduction from baseline ≥ 10 mmHg) at week 8 as the effectiveness measurement. RESULTS: In this sort-term study a significantly higher reduction of DBP was achieved with olmesartan (-11.5 mmHg, n = 145) than with losartan
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PCV43 THE IMPACT OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN USAGE ON OUTCOMES OF TREATMENT MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES (ACS) IN

PCV47 DECISION ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE
Goehler A 1 , Dietz R 1 , Osterziel KJ 1 , Siebert U 2 1 Charitè Campus Virchow Klinikum, Berlin, Germany; 2 Harvard Medical School, Boston, MA, USA OBJECTIVES: Congestive heart failure (CHF) is the leading cause for hospitalization in the elderly. In a meta-analysis of 16 randomized controlled trials (RCT) investigating disease management programs (DMP) in the treatment of CHF, we previously demonstrated a statistically significant reduction in mortality and rehospitalization, but cost-effectiveness of DMPs remains uncertain. Therefore, we sought to evaluate life expectancy and life long medical costs for DMPs. METHODS: Design: Cost and cost-effectiveness analysis using a 6 state Markov Model representing the number of prior hospitalizations (h = 1 to h = 4+) and death. Data sources: Pooled efficacy data from our meta-analyses of RCTs, SOLVD registry data for agedependent hospitalizations and mortality rates adjusted for additional benefit from beta-blocker therapy and reimbursement costs in the Australian health care system. Target population: Patients that have been admitted with CHF. Time horizon: lifetime. Perspective: societal. Intervention: conventional therapy and DMP. Outcome measures: Life years gained (LYG) and lifelong direct medical costs. RESULTS: For a population aged 73 at onset of CHF (27% female, 33% on beta-blocker), our model yielded, on average, a remaining life expectancy of 3.24 years for conventional therapy and 3.38 years for DMP. Mean undiscounted lifetime costs per patient were estimated at 11,600€ and 12,700€ respectively. The discounted incremental costeffectiveness ratio (ICER) of DMP vs. conventional care was 8813€ per LYG. Assuming the benefit due to DMP lasting for 5 years after the end of the actual intervention would lead to additional 5 life-months and reduce ICER to 4021€/LYG. CON-CLUSIONS: Based on our decision analysis, DMPs prolong life, but increase life-time costs. A cost-saving effect of DMPs as suggested in some original studies could not be confirmed. However, even under conservative assumptions regarding the duration of DMP, these programs are cost-effective when compared to other well-accepted medical interventions in heart disease.
PCV48 ARIAL FIBRILLATION HISTORY AND ATRIOVENTRICULAR BLOCK APPEARANCE IN PATIENTS WITH SINUS NODE DISEASE AND SINGLE CHAMBER ATRIAL PACEMAKER-IMPACT ON COST OF THERAPY
Rucinski P 1 , Kutarski A 2 1 Medical University of Lublin, Lublin, Poland, Poland; 2 Medical University of Lublin, Lublin, Poland OBJECTIVES: Sinus Node Disease (SND) is a common indication for implantation of a permanent pacemaker. In case of subsequent development of atrioventricular block (AVB) it is necessary to upgrade atrial pacemaker (AAI) to dual-chamber (DDD). The aim of the study was to evaluate the influence of atrial fibrillation (AF) history on the risk of AVB development in patients with SND and permanent AAI and its impact on pacing therapy costs. METHODS: Data of 752 patients with SND who had AAI implanted between 1993 and 1997 were identified. The history of AF was established on the basis of preoperative exam. The records of patients were examined to find cases that required further procedure to upgrade AAI to DDD. The cost analysis was performed to assess the strategy of primary DDD implantation in those patients with SND that would receive AAI as a standard. The costs taken into consideration were: pacemaker, leads, implantation procedure, hospitalization. The analysis of sensitivity for main partial costs was performed, future costs were discounted. RESULTS: In the whole group of 752 pts-144 pts (19.1%) required the upgrade procedure. A total of 417 pts (55.5%) had a history of AF. A total of 105 pts had the subsequent DDD pacemaker implanted in the AF group (25.2%) and 39 in the group with no AF history (11.6%). There were savings of 82€ per patient, in the primary AAI implantation arm, in the whole group and 190€ Euro in the no-AF group whereas both strategies were equal in the group with AF history. CONCLU-
